Examining the frequency and concomitant dose of geometric verification imaging for patients undergoing proton beam therapy for ocular tumours; an audit of current clinical practice

OBJECTIVESThis paper uses clinical audit to determine the extent and dosimetric impact of additional imaging for patients undergoing ocular proton beam therapy who have no clips visible in the collimated beam. METHODSAn audit was conducted on 399 patients treated at The National Centre for Eye Proton Therapy between 3 July 2017 and 14 June 2019. The mean total number of image pairs over the course of treatment for patients with and without clips visible in the collimated beam were compared. RESULTSAmong 364 evaluable patients, 333 had clips visible in the collimated beam and 31 did not. There was a statistically significant increase of five image pairs required for patients with no clips visible compared with those with clips visible (mean 14.6 vs 9.6 image pairs, respectively; p = 2.74 × 10-6). This equated to an additional 1.5 mGy absorbed dose, representing an increase in secondary cancer induction risk from 0.0004 to 0.0007%. CONCLUSIONSThe small increase in concomitant dose and set-up time for patients with no clips visible in the collimated beam is not clinically significant. ADVANCES IN KNOWLEDGEThis novel work highlights clinical audit from real on-treatment geometric verification data and frequencies, rather than protocols, for ocular proton beam therapy; something not present in the literature. The simple and straightforward methodology is easily and equally applicable to clinical audits (especially those under Ionising Radiation (Medical Exposure) Regulations) for photon techniques.